Recently, someone had me look at CPT code 81493, which represents solely the CardioDx CorusCAD test ($1050). The company went bankrupt and closed in 2019 after Moldx withdrew coverage. Prior to cancelling the coverage, annual payments were substantial ($30M in 2018, a top-ten test).
The proprietary, single-lab CPT code is still alive, perhaps because no one owns it, to delete it.
And gosh, payments continue at a surprising rate, but only from the Novitas MAC and only to a few labs in Texas. Novitas's 2020 payments for the already-dead test were $2M; Novitas's 2021 payments were $1.6M, or a two-year total of $3.6M.
2021 payments were divided among 3 labs; one was a high biller of code 81408 (rare, full-sequence genes), another got half its revenue from 81493.
Novitas' current billing article A58917 specifically lists 81493 as Category I, payable. And a future update of the same article at FCSO (A58918) continues the coverage. MolD's negative LCD, which killed the company in 2019, was retired in late 2022 (L37770).
Coverage began in 2012.
